Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (The First Affiliated Hospital of Nanchang University)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Nanchang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (The First Affiliated Hospital of Nanchang University) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy. It consists of T cells harvested from a patient and genetically modified to express a humanized CAR specific for the B-lymphocyte antigen CD19. While CD19 is primarily associated with B-cell malignancies like lymphoma and leukemia, it is also expressed on a subset of myeloma cells and their progenitors. In clinical trials conducted by The First Affiliated Hospital of Nanchang University, these CD19 CAR-T cells are typically administered as part of a sequential or mixed infusion protocol alongside BCMA-targeting CAR-T cells to treat relapsed or refractory multiple myeloma, aiming to achieve deeper and more durable responses by targeting multiple antigens.
- Other names
- anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellshumanized CD19 CAR-T cellsCD19-targeting CAR-T cellsCD-19-targeting CAR-T cellsCD 19-targeting CAR-T cells
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (The First Affiliated Hospital of Nanchang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (The First Affiliated Hospital of Nanchang University).